HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

HER2-altered non-small cell lung cancer management is undergoing a significant shift with the emergence of targeted tyrosine kinase inhibitors. Zongertinib demonstrates robust efficacy, achieving a 71% response rate in previously treated patients and 77% in the frontline setting, with a favorable safety profile characterized by low discontinuation rates. While Sevabertinib also shows impressive response rates exceeding 60%, its broader inhibition of both HER2 and EGFR leads to increased gastrointestinal and dermatological toxicities. Clinical practice now emphasizes universal next-generation sequencing for all patients, regardless of smoking status or demographics, to identify actionable mutations. As these targeted therapies evolve, the focus is shifting toward optimizing sequencing strategies and managing potential resistance, mirroring advancements previously seen in EGFR-mutant lung cancer treatment. Dr. Joshua Sabari from NYU Langone Health provides clinical insights on these developments and their impact on patient care.